Results 121 to 130 of about 46,038 (143)

Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease

Journal of Crohn's and Colitis, 2013
Arnošt Komárek, Milan Lukas, Martin Bortlik   +2 more
exaly  

Clinical outcomes in sarcoidosis after cessation of infliximab treatment

Respirology, 2009
Marc Judson
exaly  

Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment

Journal of Crohn's and Colitis, 2014
Jakob Nilsson, Michael Eberhardson, Wikstrom Ann-Charlotte   +2 more
exaly  

Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease

Inflammatory Bowel Diseases, 2012
Benjamin Pariente, Matthieu Allez, Pierre Desreumaux   +2 more
exaly  

Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy

Clinical Gastroenterology and Hepatology, 2014
Severine Vermeire, Ann Gils, Niels Vande Casteele   +2 more
exaly  

Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis

Rheumatology, 2011
Laura Nuño-Nuño, Alejandro Balsa, Chamaida Plasencia-Rodríguez   +2 more
exaly  

Antibodies to Infliximab Are Associated with Lower Infliximab Levels and Increased Likelihood of Surgery in Pediatric IBD

Inflammatory Bowel Diseases, 2015
Emil Chuang, Sharat Singh, Bousvaros Athos   +2 more
exaly  

Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis

Clinical Gastroenterology and Hepatology, 2019
Walter Reinisch, Stephen Hanauer, William Sandborn   +2 more
exaly  

Treatment of Sarcoidosis With Infliximab

Chest, 2005
Marc Judson, Joseph E Mazur
exaly  

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Lancet, The, 2017
Inge Christoffer Olsen, Jørgen Jahnsen, Espen André Haavardsholm   +2 more
exaly